Compare ASML & MRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASML | MRK |
|---|---|---|
| Founded | 1984 | 2000 |
| Country | Netherlands | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 413.6B | 268.7B |
| IPO Year | N/A | 1994 |
| Metric | ASML | MRK |
|---|---|---|
| Price | $1,363.75 | $120.73 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 14 |
| Target Price | ★ $1,475.86 | $123.21 |
| AVG Volume (30 Days) | 1.3M | ★ 11.1M |
| Earning Date | 01-01-0001 | 05-05-2026 |
| Dividend Yield | 0.46% | ★ 2.80% |
| EPS Growth | N/A | ★ 8.01 |
| EPS | N/A | ★ 7.28 |
| Revenue | N/A | ★ $65,011,000,000.00 |
| Revenue This Year | $16.35 | $3.66 |
| Revenue Next Year | $18.04 | $5.28 |
| P/E Ratio | $50.62 | ★ $16.69 |
| Revenue Growth | N/A | ★ 1.31 |
| 52 Week Low | $578.51 | $75.40 |
| 52 Week High | $1,547.22 | $125.14 |
| Indicator | ASML | MRK |
|---|---|---|
| Relative Strength Index (RSI) | 44.22 | 56.39 |
| Support Level | $1,316.06 | $76.90 |
| Resistance Level | $1,493.99 | N/A |
| Average True Range (ATR) | 40.32 | 2.65 |
| MACD | -14.92 | -0.51 |
| Stochastic Oscillator | 16.84 | 50.00 |
ASML is the market leader in lithography systems for manufacturing semiconductors. Lithography is the process in which a light source is used to expose circuit patterns from a photo mask onto a semiconductor wafer. Lithography allows chipmakers to increase the number of transistors on the same area of silicon, with lithography historically representing a high portion of the cost of making cutting-edge chips. ASML outsources the manufacturing of most of its parts, acting like an assembler. ASML's largest clients are TSMC, Samsung, and Intel.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).